On July 14, 2025, Sarepta Therapeutics announced a significant restructuring plan including a workforce reduction of about 36%, expecting to incur one-time costs between $32 million and $37 million due to employee termination benefits. This restructuring also led to several management appointments, effective July 16, 2025.